LEONABIO INC (LONA) Fundamental Analysis & Valuation

NASDAQ:LONA • US04746L2034

Current stock price

8.97 USD
-0.71 (-7.33%)
At close:
8.97 USD
0 (0%)
After Hours:

This LONA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LONA Profitability Analysis

1.1 Basic Checks

  • LONA had negative earnings in the past year.
  • LONA had a negative operating cash flow in the past year.
  • In the past 5 years LONA always reported negative net income.
  • In the past 5 years LONA always reported negative operating cash flow.
LONA Yearly Net Income VS EBIT VS OCF VS FCFLONA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • LONA has a worse Return On Assets (-125.61%) than 79.79% of its industry peers.
  • The Return On Equity of LONA (-140.83%) is worse than 67.88% of its industry peers.
Industry RankSector Rank
ROA -125.61%
ROE -140.83%
ROIC N/A
ROA(3y)-91.8%
ROA(5y)-59.81%
ROE(3y)-115.75%
ROE(5y)-74.32%
ROIC(3y)N/A
ROIC(5y)N/A
LONA Yearly ROA, ROE, ROICLONA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

  • LONA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LONA Yearly Profit, Operating, Gross MarginsLONA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

6

2. LONA Health Analysis

2.1 Basic Checks

  • LONA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, LONA has more shares outstanding
  • LONA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LONA Yearly Shares OutstandingLONA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
LONA Yearly Total Debt VS Total AssetsLONA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -7.86, we must say that LONA is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -7.86, LONA is doing worse than 65.28% of the companies in the same industry.
  • LONA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.86
ROIC/WACCN/A
WACCN/A
LONA Yearly LT Debt VS Equity VS FCFLONA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 9.70 indicates that LONA has no problem at all paying its short term obligations.
  • LONA's Current ratio of 9.70 is fine compared to the rest of the industry. LONA outperforms 79.27% of its industry peers.
  • LONA has a Quick Ratio of 9.70. This indicates that LONA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of LONA (9.70) is better than 79.79% of its industry peers.
Industry RankSector Rank
Current Ratio 9.7
Quick Ratio 9.7
LONA Yearly Current Assets VS Current LiabilitesLONA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

1

3. LONA Growth Analysis

3.1 Past

  • LONA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.04%, which is quite impressive.
EPS 1Y (TTM)66.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, LONA will show a very strong growth in Earnings Per Share. The EPS will grow by 24.21% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y78.17%
EPS Next 2Y35.49%
EPS Next 3Y24.21%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LONA Yearly Revenue VS EstimatesLONA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 10K 20K 30K 40K 50K
LONA Yearly EPS VS EstimatesLONA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

1

4. LONA Valuation Analysis

4.1 Price/Earnings Ratio

  • LONA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LONA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LONA Price Earnings VS Forward Price EarningsLONA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LONA Per share dataLONA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

  • LONA's earnings are expected to grow with 24.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.49%
EPS Next 3Y24.21%

0

5. LONA Dividend Analysis

5.1 Amount

  • LONA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

LONA Fundamentals: All Metrics, Ratios and Statistics

LEONABIO INC

NASDAQ:LONA (3/27/2026, 8:00:00 PM)

After market: 8.97 0 (0%)

8.97

-0.71 (-7.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19
Earnings (Next)05-07
Inst Owners48.59%
Inst Owner ChangeN/A
Ins Owners1.62%
Ins Owner Change26.04%
Market Cap83.78M
Revenue(TTM)N/A
Net Income(TTM)-37.72M
Analysts80
Price Target10.2 (13.71%)
Short Float %0.52%
Short Ratio0.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.52%
Min EPS beat(2)-35%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)-3.44%
Min EPS beat(4)-35%
Max EPS beat(4)13.23%
EPS beat(8)6
Avg EPS beat(8)3.86%
EPS beat(12)8
Avg EPS beat(12)3.02%
EPS beat(16)12
Avg EPS beat(16)4.55%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)-49.32%
EPS NQ rev (3m)N/A
EPS NY rev (1m)16.56%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.13
P/tB 3.13
EV/EBITDA N/A
EPS(TTM)-9.68
EYN/A
EPS(NY)-4.16
Fwd EYN/A
FCF(TTM)-5.6
FCFYN/A
OCF(TTM)-5.6
OCFYN/A
SpS0
BVpS2.87
TBVpS2.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -125.61%
ROE -140.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-91.8%
ROA(5y)-59.81%
ROE(3y)-115.75%
ROE(5y)-74.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.7
Quick Ratio 9.7
Altman-Z -7.86
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)56.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.6%
EPS Next Y78.17%
EPS Next 2Y35.49%
EPS Next 3Y24.21%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y64.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.92%
OCF growth 3YN/A
OCF growth 5YN/A

LEONABIO INC / LONA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LEONABIO INC (LONA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LONA.


What is the valuation status of LEONABIO INC (LONA) stock?

ChartMill assigns a valuation rating of 1 / 10 to LEONABIO INC (LONA). This can be considered as Overvalued.


How profitable is LEONABIO INC (LONA) stock?

LEONABIO INC (LONA) has a profitability rating of 0 / 10.


Can you provide the financial health for LONA stock?

The financial health rating of LEONABIO INC (LONA) is 6 / 10.